Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease ...

Clinical validation of stem cell reactivation approach positions Pelage as leader in regenerative medicine and aging ...

SKY-0515 is an oral small molecule designed to reduce the production of both huntingtin (HTT) and PMS1 proteins—two key drivers of HD pathology ...

PHILADELPHIA, PA, USA I June 17, 2025 I Integral Molecular, the industry leader in discovering antibodies against membrane proteins, is pleased to announce ...

SANTIAGO DE COMPOSTELA, Spain & SHANGHAI, China I June 17, 2025 I SunRock Biopharma and Escugen have joined forces in a strategic partnership to ...

Interim data on the cancer treatment shows robust potential for balancing efficacy and safety. TAIPEI, Taiwan and SHANGHAI, China and SAN FRANCISCO, CA, USA I June 17, 2025 I Foll ...

SOUTH SAN FRANCISCO, CA, USA I June 16, 2025 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome ...

I Orion Corporation and Glykos Finland Oy today announced that they have extended their research collaboration and licensing agreement for the ...

First patient dosed with Debiopharm’s first-in-class CD37 targeted antibody drug conjugate (ADC) in a Phase 1/2, multicenter, open-label trial, for patients ...

Independent Data Monitoring Committee (DMC) has approved continuation of trial as planned with no modifications ...

ROCKVILLE, MD and CAMBRIDGE, MA, USA I June 16, 2025 I Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage Therapeutics, Inc. (Nasdaq: SAGE), today ...

MILAN, Italy I June 16, 2025 I AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and ...